The stock of ARS Pharmaceuticals Inc (SPRY) has seen a -10.68% decrease in the past week, with a -20.46% drop in the past month, and a -26.24% decrease in the past quarter. The volatility ratio for the week is 7.20%, and the volatility levels for the past 30 days are at 6.32% for SPRY. The simple moving average for the last 20 days is -17.31% for SPRY stock, with a simple moving average of -3.95% for the last 200 days.
Is It Worth Investing in ARS Pharmaceuticals Inc (NASDAQ: SPRY) Right Now?
Additionally, the 36-month beta value for SPRY is 0.88. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for SPRY is 51.02M and currently, short sellers hold a 26.71% ratio of that float. The average trading volume of SPRY on December 19, 2024 was 1.07M shares.
SPRY) stock’s latest price update
ARS Pharmaceuticals Inc (NASDAQ: SPRY)’s stock price has plunge by -6.80relation to previous closing price of 11.76. Nevertheless, the company has seen a -10.68% plunge in its stock price over the last five trading sessions. globenewswire.com reported 2024-12-12 that Licensing partners in key Asia Pacific countries have filed for approval of neffy (epinephrine nasal spray) 2 mg with regulatory agencies Licensing partners in key Asia Pacific countries have filed for approval of neffy (epinephrine nasal spray) 2 mg with regulatory agencies
Analysts’ Opinion of SPRY
Raymond James, on the other hand, stated in their research note that they expect to see SPRY reach a price target of $22, previously predicting the price at $18. The rating they have provided for SPRY stocks is “Strong Buy” according to the report published on August 13th, 2024.
Leerink Partners gave a rating of “Outperform” to SPRY, setting the target price at $20 in the report published on August 12th of the current year.
SPRY Trading at -24.26% from the 50-Day Moving Average
After a stumble in the market that brought SPRY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -40.79% of loss for the given period.
Volatility was left at 6.32%, however, over the last 30 days, the volatility rate increased by 7.20%, as shares sank -20.52% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -21.04% lower at present.
During the last 5 trading sessions, SPRY fell by -10.68%, which changed the moving average for the period of 200-days by +23.42% in comparison to the 20-day moving average, which settled at $13.25. In addition, ARS Pharmaceuticals Inc saw 100.00% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SPRY starting from Chakma Justin, who sale 117,333 shares at the price of $12.27 back on Dec 12 ’24. After this action, Chakma Justin now owns 136,380 shares of ARS Pharmaceuticals Inc, valued at $1,439,124 using the latest closing price.
Chakma Justin, the Chief Business Officer of ARS Pharmaceuticals Inc, sale 27,272 shares at $12.06 during a trade that took place back on Dec 13 ’24, which means that Chakma Justin is holding 136,380 shares at $328,968 based on the most recent closing price.
Stock Fundamentals for SPRY
Current profitability levels for the company are sitting at:
- -23.84 for the present operating margin
- 0.94 for the gross margin
The net margin for ARS Pharmaceuticals Inc stands at -19.35. The total capital return value is set at -0.3. Equity return is now at value -22.41, with -21.07 for asset returns.
Currently, EBITDA for the company is -67.45 million with net debt to EBITDA at 0.65. When we switch over and look at the enterprise to sales, we see a ratio of 404.1. The receivables turnover for the company is 3.28for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.54.
Conclusion
In conclusion, ARS Pharmaceuticals Inc (SPRY) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
